SynthesisObesity surgery2017
The Influence of the Orbera Intragastric Balloon Filling Volumes on Weight Loss, Tolerability, and Adverse Events: a Systematic Review and Meta-Analysis.
Synthesis in Obesity surgery, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06673550 (Fluid-filled Intragastric Balloon's Filling Volume At 500, 600, or 700 Ml for Treatment of Overweight and Obesity), which is not on this map. Cited by 35 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Fluid-filled Intragastric Balloon's Filling Volume At 500, 600, or 700 Ml for Treatment of Overweight and Obesity: Which is the Magic Number? a Single Centre Randomized Study
Who cites it
35 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Effectiveness and Safety of the Allurion Swallowable Intragastric Balloon for Short-term Weight Loss: A Systematic Review and Meta-analysis.Obesity surgery · 2024Pooled it
- Efficacy and safety of very low calorie ketogenic diet (VLCKD) in patients with overweight and obesity: A systematic review and meta-analysis.Reviews in endocrine & metabolic disorders · 2020Pooled it
- Intragastric Balloon Treatment Enhances Weight Maintenance Adjunct to Low-Energy Diet and Group-Based Cognitive Behavioural Therapy: A Randomized Controlled Trial.Diabetes, obesity & metabolism · 2026Trial
- Intragastric Balloon for Treatment of Overweight and Obesity: Which Is the Best Filling Volume? A Single-Center Randomized Study.Obesity surgery · 2025Trial
- Intragastric Balloon Placement Induces Significant Metabolic and Histologic Improvement in Patients With Nonalcoholic Steatohepatitis.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2021Trial
- Endoscopy for Metabolic Diseases.Journal of clinical medicine · 2026Review
- Endoscopic bariatrics: Current status and emerging technologies.World journal of gastrointestinal endoscopy · 2025Review
- Impact of Bariatric Surgery and Endoscopic Therapies on Liver Health in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Review.Journal of clinical medicine · 2025Review
- The evolution and current state of bariatric endoscopy in Western countries.Clinical endoscopy · 2024Review
- Endoscopic tips for intragastric balloon use for obesity: what you need to know.VideoGIE : an official video journal of the American Society for Gastrointestinal Endoscopy · 2024Review
- Intragastric Balloon as a First Step Before Metabolic Bariatric Surgery in Patients with BMI ≥ 50 kg/mObesity surgery · 2024Article
- Evaluating the Safety of the Intragastric Balloon: Spanish Multicenter Experience in 20,680 Cases and with 12 Different Balloon Models.Obesity surgery · 2024Article
- Weight regain after intragastric balloon for pre-surgical weight loss.World journal of gastrointestinal surgery · 2024Article
- Metabolic and Bariatric Endoscopy: A Mini-Review.Life (Basel, Switzerland) · 2023Review
- Losing weight to achieve joint or hernia surgery: is the intragastric balloon the answer?Surgical endoscopy · 2023Article
- A Comprehensive Review on Bariatric Endoscopy: Where We Are Now and Where We Are Going.Medicina (Kaunas, Lithuania) · 2023Review
- Intragastric Balloon in Obese Compensated Nonalcoholic Steatohepatitis Cirrhosis Patients Is Safe and Achieves Significant Weight Reduction at 6-Months.Digestive diseases and sciences · 2023Article
- Article
- Endoscopic Bariatric and Metabolic Therapies for Liver Disease: Mechanisms, Benefits, and Associated Risks.Journal of clinical and translational hepatology · 2022Review
- Gastric Balloon Implantation as Part of Morbid Adiposity Therapy Changes the Structure of the Stomach Wall.Visceral medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe Orbera intragastric balloon (IGB) has been approved by the US Food and Drug Administration for use in patients with a body mass index (BMI) between 30 and 40 kg/m
methodsA systematic review of studies investigating the use of the Orbera IGB system for obesity treatment was performed. Data was examined using random effects modelling and meta-regression analyses.
resultsForty-four studies (n = 5549 patients) reported BFV and % total body weight loss (TBWL) at 6 months. Pooled %TBWL at 6 months was 13.2% [95% CI 12.3-14.0]. A funnel plot demonstrated a low risk of publication bias. Meta-regression showed no statistically significant association between filling volume and %TBWL at 6 months (p = 0.268). Higher BFV was associated with lower rates of esophagitis (slope = -0.008, p < 0.001) and prosthesis migration (slope = -0.015, p < 0.001). There was no association between BFV and early removal (p = 0.1), gastroesophageal reflux symptom (p = 0.64), or ulcer rates (p = 0.09).
conclusionsNo association was observed between Orbera IGB filling volume and weight loss outcomes. Higher volumes appear to be associated with lower migration and esophagitis rates; thus, a balloon filling volume of 600-650 mL is recommended.
Indexed as
Identifiers
28285471What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.